The global infertility drugs market, valued at USD 3,699.8 million in 2023, is projected to achieve significant growth, reaching USD 6,814.68 million by 2033. According to recent market analysis, this represents a compound annual growth rate (CAGR) of 6.3% during the forecast period. The increasing prevalence of infertility among both men and women is fueling the demand for effective infertility treatments.
Factors Driving Market Growth:
Infertility, affecting individuals of both genders, stems from various causes:
- Female Infertility: Aging, polycystic ovarian syndrome (PCOS), obesity, and a history of miscarriages.
- Male Infertility: Erectile dysfunction, low sperm count, and abnormal sperm production.
To address these challenges, researchers and market leaders are introducing innovative treatments. A notable breakthrough includes research by BGU scientists, who developed a new treatment stimulating telomerase expression to protect cells and improve fertility outcomes.
Pioneering Innovations in Infertility Treatments:
Several pharmaceutical companies are leading the charge with first-in-class infertility solutions:
- Oxolifeβs OXO-001: Designed to enhance embryo implantation by improving binding with the uterine lining.
- Ferring Pharmaceuticalsβ Trisequens: A novel fertility treatment tailored to improve conditions for embryo implantation, addressing critical needs in assisted reproduction.
In addition, in-vitro fertilization (IVF) is becoming a mainstream treatment option, significantly contributing to the market’s expansion. IVFβs success in overcoming fertility challenges is further supported by advancements in hormonal treatments and specialized medications.
Lifestyle Trends and Regulatory Challenges:
The rising prevalence of sedentary lifestyles, hormonal imbalances, and PCOS has increased the demand for effective infertility drugs. However, growth is tempered by stringent regulatory frameworks for product approvals and the high costs of patented treatments, presenting challenges for manufacturers and healthcare providers.
Future Outlook:
With continued innovation, the availability of diverse infertility treatments, and increasing awareness of fertility issues, the global infertility drugs market is poised for robust growth. Industry stakeholders remain focused on addressing regulatory hurdles while advancing affordable, effective solutions to meet growing demand.
Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends!
Key Takeaways from Market Study:
- The infertility drugs market is expected to record a CAGR of 6.3% over the forecast period.
- According to estimates, the infertility drugs market in North America may remain strong throughout the length of the forecast period.
- The gonadotropins segment dominated the infertility drugs market with a revenue share of 40.1% in 2023 and is expected to grow rapidly.
- The womenβs segment dominated the market for infertility drugs in 2023 with a revenue share of 71.3%.
Competitive Landscape:
Several prominent companies dominate this market, including Ferring Pharmaceuticals Inc., Merck KGaA, Bayer AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Theramex, Novartis AG., Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co., Mankind Pharma Ltd., and others.
Recent Developments:
- Genea Biomedx (Australia) partnered with Hamilton Thorne in 2020 to sell its fertility products in the United States and Canada.
- The Pergoveris Pen is the first pen injector for gonadotropins, which are hormones that play a crucial role in reproduction and fertility. It was introduced to India in August 2021 by Merck, to treat infertility.
- The Fertility Partners, the leading provider of fertility services in Canada, has partnered with Maven Clinic to form a referral network for fertility clinics. Maven’s network helps its members find high-quality fertility care in over 70 countries. The company also launched MavenRx, its new medication service, in February 2020, to help fertility members get their medications more seamlessly.
Infertility Drugs Market Segmentation by Category:
By Drug Class:
- Gonadotrophins
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Biguanides
- Other Drug Classes
By End User:
- Male
- Female
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Other Distribution Channels
By Region Outlook:
- North America
- Latin America
- Europe
- The Middle East and Africa
- East Asia
ππ±π©π₯π¨π«π π ππβπ¬ πππ₯ππππ ππ§π π¨π’π§π ππ¨π―ππ«ππ π π¨π§ ππππ₯ππ‘πππ«π πππ«π€ππ ππ§π¬π’π π‘ππ¬ ππ¨π¦ππ’π§:
Women Digital Health Solutions Industry
Oxygen Conservation Devices Industry
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:Β Β Β Β Β Β Β Β
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries:Β sales@futuremarketinsights.com
Website:Β https://www.futuremarketinsights.com
LinkedIn|Β Twitter|Β Blogs | YouTube